
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. is projected to experience significant revenue growth across its major streams, with estimated increases of 24% for systems, 20% for disposables, and 25% for service and accessories by FY26, driven by greater system adoption and catheter utilization. The company's remarkable performance in the second quarter, showcasing a 95% year-over-year revenue increase to $8.8 million, alongside a robust 35% rise in recurring revenue, underscores its strong market position and demand for innovative products such as the Map-iT and MAGiC catheters. Furthermore, Stereotaxis's regulatory advancements and successful product launches position it for enhanced business leverage and the expectation of exceeding $10 million in average quarterly revenue by FY26, further reinforcing a positive financial outlook.
Bears say
Stereotaxis Inc. faces a negative outlook primarily due to significant operational challenges, including delays in product approvals and ongoing supply issues with essential catheters, which may adversely affect revenue projections. The company's net loss of $3.8 million reflects its current financial struggles further compounded by the need to seek additional financing within a two-year cash runway to support its sales infrastructure and operational expenses. Additionally, the potential for reduced reimbursement rates, competition from both manual and robotic systems, and slower adoption rates internationally present further risks that could hinder the company's profitability trajectory and overall financial performance.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares